717 related articles for article (PubMed ID: 24720101)
1. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis.
Kraicer-Melamed H; O'Donnell S; Quach C
Vaccine; 2016 Mar; 34(13):1540-1550. PubMed ID: 26899372
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study.
Steens A; Vestrheim DF; de Blasio BF
Epidemics; 2015 Jun; 11():24-31. PubMed ID: 25979279
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
[TBL] [Abstract][Full Text] [Related]
6. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?
Borrow R; Heath PT; Siegrist CA
Curr Opin Infect Dis; 2012 Jun; 25(3):292-303. PubMed ID: 22517603
[TBL] [Abstract][Full Text] [Related]
7. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
9. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
11. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
[TBL] [Abstract][Full Text] [Related]
12. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.
Thorrington D; van Rossum L; Knol M; de Melker H; Rümke H; Hak E; van Hoek AJ
PLoS One; 2018; 13(2):e0192640. PubMed ID: 29425249
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children.
Muhammad RD; Oza-Frank R; Zell E; Link-Gelles R; Narayan KM; Schaffner W; Thomas A; Lexau C; Bennett NM; Farley MM; Harrison LH; Reingold A; Hadler J; Beall B; Klugman KP; Moore MR
Clin Infect Dis; 2013 Mar; 56(5):e59-67. PubMed ID: 23155149
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
Sings HL
Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
[TBL] [Abstract][Full Text] [Related]
16. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
18. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
